

## Special Issue

# Nanomedicine Progress in Tumor Treatment

### Message from the Guest Editor

In the era of precision medicine, hard nanomaterials (HNMs) have emerged as crucial allies for the treatment of different types of cancer. Due to their nanoscopic dimension, HNMs can preferentially accumulate in the tumoral tissues as an extensively useful for drug or gene delivery. Additionally, depending on size, shape, composition, and functionalization, HNMs have been used for active tumor targeting and cancer imaging, or as nano-photosensitizers. More recently, the interaction of HNMs with the immune system has been investigated, showing that these nanosized objects can induce a positive immunological response. Developing of more complex architectures for the precise design of multifunctional nanomaterials is highly desirable for cancer treatment. Additionally, understanding the complexity of HNMs interaction within the biological environment, their targeting and pharmacological efficacy, and their biosafety will support the development of the next generation of strategies to significantly improve the antitumor activity. This Special Issue aims to highlight recent advances in HNMs application in cancer treatment.

### Guest Editor

Dr. Giacomo Reina

Graduate School of Human and Environmental Studies, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan

### Deadline for manuscript submissions

closed (20 February 2023)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/108060](https://mdpi.com/si/108060)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)